Congress objections to US imaging cuts
This article was originally published in Clinica
Executive Summary
US industry association AdvaMed says it is heartened that 69 members of Congress have written to House speaker Nancy Pelosi to express serious concerns about the impact of additional cuts (in the so-called CHAMP Act) in medical imaging services on patients. A bipartisan group has also expressed support for the Access to Medicare Imaging Act of 2007 (HR 1293), which has 169 sponsors in the House and would impose a two-year moratorium on the Deficit Reduction Omnibus Reconciliation Act (DRA) payment reductions while an impact study is ongoing. Reimbursement has been cut already this year (see Clinica No 1236, p 2). The association supports instead an accreditation programme and appropriateness criteria to help keep costs down.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.